Aromatase inhibitors to augment height: Continued caution and study required

JCRPE Journal of Clinical Research in Pediatric Endocrinology

Volumn 1, Issue 6, 2009, Pages 256-261

  Geffner, Mitchell E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Androgen; Aromatase; Estrogen; Gonadotropin releasing hormone agonists; Inhibitors

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FADROZOLE; FORMESTANE; GROWTH PROMOTOR; LETROZOLE; TESTOLACTONE; TESTOSTERONE; VOROZOLE;

ADRENAL SUPPRESSION; CLINICAL TRIAL; DELAYED PUBERTY; DRUG EFFICACY; DRUG SAFETY; EPIPHYSIS; FEVER; GROWTH HORMONE DEFICIENCY; GROWTH PLATE; HEIGHT; HUMAN; LETHARGY; MEDICAL RESEARCH; NAUSEA; NONHUMAN; RASH; REVIEW; SHORT STATURE; SIDE EFFECT; SPERMATOZOON COUNT; UNSPECIFIED SIDE EFFECT; VERTEBRA MALFORMATION;

AROMATASE INHIBITORS; FEMALE; GROWTH DISORDERS; HUMANS; MALE;

EID: 77953462712     PISSN: 13085727     EISSN: 13085735     Source Type: Journal    
DOI: 10.4274/jcrpe.v1i6.256     Document Type: Review

References (27)

1. Franklin SL, Geffner ME. Growth hormone: The expansion of available products and indications. Endocrinol Metab N Amer, 2009;38:587-611. [Abstract] / [Full Text] / [PDF]
2. Normal at any cost. Cohen S and Cosgrove C. New York, Penguin Group (USA), 2009;269-305. [Abstract]
3. Yanovski JA, Rose SR, Municchi G, Pescovitz OH, Hill SC, Cassorla FG, Cutler GB Jr. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003;348:908-917. [Abstract] / [Full Text] / [PDF]
4. Carel JC. Management of short stature with GnRH agonist and co-treatment with growth hormone: a controversial issue. Mol Cell Endocrinol 2006;254-255:226-233. [Abstract] / [PDF]
5. van Gool SA, Kamp GA, Visser-van Balen H, Mul D, Waelkens JJ, Jansen M, Verhoeven-Wind L, Delemarre-van de Waal HA, de Muinck Keizer-Schrama SM, Leusink G, Roos JC, Wit JM. Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. J Clin Endocrinol Metab 2007;92:1402-1408. [Abstract] / [Full Text] / [PDF]
6. Tanaka T. Sufficiently long-term treatment with combined growth hormone and gonadotropin-releasing hormone analog can improve adult height in short children with isolated growth hormone deficiency (GHD) and in non-GHD short children. Pediatric Endocr Rev 2007;5:471-481. [Abstract]
7. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056-1061. [Abstract]
8. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-3698. [Abstract] / [Full Text]
9. Grumbach MM. Mutations in the synthesis and action of estrogen: the critical role in the male of estrogen on pubertal growth, skeletal maturation, and bone mass. Ann NY Acad Sci 2004;1038:7-13. [Abstract] / [Full Text] / [PDF]
10. Hong Y, Li H, Yuan YC, Chen S. Molecular characterization of aromatase. Ann NY Acad Sci 2009;1155:112-120. [Abstract] / [Full Text] / [PDF]
11. Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003;30(4 Suppl 14):3-11. [Abstract] / [Full Text] / [PDF]
12. Dunkel L. Use of aromatase inhibitors to increase final height. Mol Cell Endocrinol 2006;254-255:207-216. [Abstract] / [PDF]
13. Damiani D, Ramos Garcia PC. New metabolic and endocrine approaches in pediatrics. J Pediatr (Rio J) 2007;83(5 Suppl):S117-118. [Abstract] / [PDF]
14. Geffner ME. For debate: Aromatase inhibitors to augment height: have we lost our inhibitions? Pediatr Endocrinol Rev 2008;5:756-759. [Abstract]
15. Shulman DI, Francis GL, Palmert MR, Eugster EA; Lawson Wilkins Pediatric Endocrine Society Drug and Therapeutics Committee. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics 2008;121:4:e975-e983. [Abstract] / [Full Text] / [PDF]
16. Dunkel L. Update on the role of aromatase inhibitors in growth disorders. Horm Res 2009;7(suppl 1):57-63. [Abstract] / [Full Text] / [PDF]
17. Wickman S, Sipil‰ I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001;357:1743-1748. [Abstract] / [Full Text] / [PDF]
18. Mauras N, Lima J, Patel D, Rini A, di Salle E, Kwok A, Lippe B. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 2003;88:5951-5956. Erratum in: J Clin Endocrinol Metab 2004;89:732. [Abstract] / [Full Text] / [PDF]
19. Karmazin A, Moore WV, Popovic J, Jacobson JD. The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. J Pediatr Endocrinol Metab 2005;18:285-293. [Abstract]
20. Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006;64:510-513. [Abstract] / [Full Text] / [PDF]
21. Mauras N, Gonzalez de Pijem L, Hsiang HY, Desrosiers P, Rapaport R, Schwartz ID, Klein KO, Singh RJ, Miyamoto A, Bishop K. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008;93:823-831. [Abstract] / [Full Text] / [PDF]
22. Wickman S, Saukkonen T, Dunkel L. The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. Eur J Endocrinol 2002;146:339-346. [Abstract] / [PDF]
23. Wickman S, Kajantie E, Dunkel L. Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab 2003;88:3785-3793. [Abstract] / [PDF]
24. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005;90:6396-6402. [Abstract] / [Full Text] / [PDF]
25. Matti Hero, Outi Mäkitie, Heikki Kröger, Elina Nousiainen, Sanna Toiviainen-Salo, Leo Dunkel. Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm Res 2009;71:290-297. [Abstract] / [Full Text] / [PDF]
26. Eddy EM, Washburn TF, Bunch DO, Goulding EH, Gladen BC, Lubahn DB, Korach KS. Targeted disruption of the estrogen receptor gene in male mice causes alteration of spermatogenesis and infertility. Endocrinology 1996;137: 4796-4805. [Abstract] / [Full Text]
27. Mauras N, Bell J, Snow BG, Winslow KL. Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls. Fertil Steril 2005;84:239-242. [Abstract] / [Full Text] / [PDF]